Deal Watch: Bristol Continues Push Into Fibrotic Disease Area
Executive Summary
Novartis and Amgen exchange rights around CNS candidates in Alzheimer’s and migraine. AstraZeneca out-licenses global rights, except for Japan and Asia, for Phase III psoriasis candidate brodalumab to Valeant.
You may also be interested in...
Bristol’s Fibrotic Game Plan: Promedior Acquisition Hinges On Phase II Results
Bristol’s third deal in anti-fibrosis field in past year could give it intravenous, disease-modifying candidate for myelofibrosis and idiopathic fibrosis.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.